The Technical Analyst
Belite Bio, Inc [BLTE]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Belite Bio, Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
3.57% $39.75
America/New_York / 26 apr 2024 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 182.73 mill |
| EPS: | -1.190 |
| P/E: | -33.40 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 29.75 mill |
| Avg Daily Volume: | 0.0487 mill |
| RATING 2024-04-26 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -33.40 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -5.68x |
| Company: PE -33.40 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.28 (-91.74%) $-36.47 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 37.43 - 42.07 ( +/- 5.83%) |
| ATR Model: 14 days |
Forecast:
16:00 - $39.75
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $39.75
Forecast 2: 16:00 - $39.75
Forecast 3: 16:00 - $39.75
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $39.75 (3.57% ) |
| Volume | 0.0465 mill |
| Avg. Vol. | 0.0487 mill |
| % of Avg. Vol | 95.35 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BLTE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | buy | $45.99 | N/A | Active |
|---|
BLTE
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Latest Press Releases
2024-04-25 19:15:00 - Press Release
Belite Bio Announces $25 Million Registered Direct Offering
San diego, april 25, 2024 (globe newswire) -- belite bio, inc (nasdaq: blte) (“belite bio” or the “company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has entered into a securities purchase agreement with an institutional investor, for the purchase and sale of up to an aggregate of 651,380 american depositary shares of the company (“adss”), each ads representing one ordinary share of the company at a purchase price of $38.38 per ads, and the warrants to purchase up to an aggregate of 651,380 adss, which will have an initial exercise price equal to $44...
2024-03-22 08:00:00 - Press Release
Belite Bio Announces Pmda Submission Of Tinlarebant For Stargardt Disease Clinical Trial In Japan
San diego, march 22, 2024 (globe newswire) -- belite bio, inc (nasdaq: blte) (“belite bio” or the “company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announces its submission to the pharmaceuticals and medical devices agency (pmda) to initiate a clinical trial of tinlarebant in adolescent stgd1 in japan (“dragon ii”).
2024-03-11 22:28:00 - Press Release
Belite Bio Announces Availability Of Annual Report On Form 20-f Through Company Website
San diego, march 11, 2024 (globe newswire) -- belite bio, inc (nasdaq: blte), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its annual report on form 20-f, containing audited consolidated financial statements for the year ended december 31, 2023, as filed with the securities and exchange commission on march 11, 2024, is available through its website (https://www.belitebio.com). shareholders may receive a hard copy of the annual report free of charge upon request. this press release is being issued pursuant to nasdaq listing rule 5250(d)(1)(c).
2024-03-11 21:27:00 - Press Release
Belite Bio Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Corporate Update
San diego, march 11, 2024 (globe newswire) -- belite bio, inc (nasdaq: blte) (“belite bio” or the “company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its audited financial results for full-year 2023 and the unaudited and unreviewed financial results for the quarter ended december 31, 2023, and provided a business update.
2024-03-06 08:00:00 - Press Release
Belite Bio To Host Webcast On March 12, 2024, To Discuss Fourth Quarter And Full Year 2024 Financial Results
San diego, march 06, 2024 (globe newswire) -- belite bio, inc (nasdaq: blte), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on tuesday, march 12, 2024, at 4:30 p.m. eastern time to discuss the company's financial results and provide a business update for the fourth quarter and full year ended december 31, 2023.
Latest News
2024-04-10 10:56:03 - Zacks Investment Research
Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect?
The consensus price target hints at a 41.1% upside potential for Belite Bio (BLTE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-03-12 19:53:07 - Seeking Alpha
Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript
2024-03-06 08:00:00 - GlobeNewsWire
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, March 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update for the fourth quarter and full year ended December 31, 2023.
2024-02-07 08:00:00 - GlobeNewsWire
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
SAN DIEGO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13-14 and conduct a virtual presentation. The virtual presentation will take place on Wednesday, February 14, 2024, at 12:40 pm ET.
2023-11-14 23:30:05 - Seeking Alpha
Belite Bio, Inc (BLTE) Q3 2023 Earnings Call Transcript
Belite Bio, Inc. (NASDAQ:BLTE ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Jennifer Kim - Kento Basma Radwan - Leerink Partners Yi Chen - HC Wainwright Bruce Jackson - The Benchmark Company Operator Hello and thank you for joining us to discuss Belite's Third Quarter 2023 Financial Results. Joining the call is Dr. Tom Lin, Chairman and CEO, Dr. Nathan Mata, Chief Scientific Officer, and Hao-Wan Zhang, Chief Financial Officer of BeLite Bio.
2023-11-07 08:00:00 - GlobeNewsWire
Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, November 14, 2023, at 4:30 p.m. Eastern Time to discuss the Company's financial results for the third quarter ended September 30, 2023, and provide a general business update.
2023-08-21 12:47:30 - Zacks Investment Research
Belite Bio (BLTE) Stock Surges 72% in a Month: Here's Why
Belite Bio (BLTE) rises 72% in a month due to encouraging progress on the development of the company's lead product candidate Tinlarebant, which is being developed to treat several eye diseases.
2023-08-13 09:45:03 - Seeking Alpha
Belite Bio, Inc (BLTE) Q2 2023 Earnings Call Transcript
Belite Bio, Inc (NASDAQ:BLTE ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Basma Radwan - Leerink Partners Jennifer Kim - Cantor Fitzgerald & Co. Yi Chen - HC Wainwright & Co, LLC Bruce Jackson - The Benchmark Company Operator Good morning, and welcome to the Belite Bio Q2 2023 Financial Results Conference Call. At this time, all attendees are in a listen-only mode.
2023-06-30 16:09:14 - The Motley Fool
Why Shares of Belite Bio Soared This Week
Investors, seeing the 52-week low, saw a bargain in Belite Bio. The company doesn't have any revenue, but it has a promising eye disease therapy.
2023-06-15 12:34:14 - Seeking Alpha
Belite Bio: Undercovered Eye Disease Company With Early Data
BLTE works with retinal disease patients. Their lead asset has positive phase 1 data. Their cash position and trial patient population are two worries.